Show simple item record

dc.contributor.authorMoreno, R.
dc.contributor.authorRojas, L.A.
dc.contributor.authorVilardell, Felip
dc.contributor.authorCervera Soriano, Vanessa
dc.contributor.authorGarcía-Castro, J.
dc.contributor.authorFajardo, C. A.
dc.contributor.authorAlemany, R.
dc.date.accessioned2021-03-22T12:19:10Z
dc.date.available2021-03-22T12:19:10Z
dc.date.issued2017
dc.identifier.issn1687-9678
dc.identifier.urihttp://hdl.handle.net/10459.1/70836
dc.description.abstractAntitumor efficacy of systemically administered oncolytic adenoviruses (OAdv) is limited due to diverse factors such as liver sequestration, neutralizing interactions in blood, elimination by the immune system, and physical barriers in tumors. It is therefore of clinical relevance to improve OAdv bioavailability and tumor delivery. Among the variety of tumor-targeting strategies, the use of stem cells and specifically bone marrow-derived mesenchymal stem cells (BM-MSCs) is of particular interest due to their tumor tropism and immunomodulatory properties. Nonetheless, the invasive methods to obtain these cells, the low number of MSCs present in the bone marrow, and their restricted in vitro expansion represent major obstacles for their use in cancer treatments, pointing out the necessity to identify an alternative source of MSCs. Here, we have evaluated the use of menstrual blood-derived mesenchymal stem cells (MenSCs) as cell carriers for regional delivery of an OAdv in the tumor. Our results indicate that MenSCs can be isolated without invasive methods, they have an increased proliferation rate compared to BM-MSCs, and they can be efficiently infected with different serotype 5-based capsid-modified adenoviruses, leading to viral replication and release. In addition, our in vivo studies confirmed the tumor-homing properties of MenSCs after regional administration.ca_ES
dc.description.sponsorshipThis work was supported by Asociación Española Contra el Cáncer (AECC), BIO2014-57716-C2-1-R grant and PI14CIII/00005 to J G-C from the Ministerio de Economía y Competitividad of Spain, Adenonet BIO2015-68990- REDT from the Ministerio de Economía y Competitividad of Spain, Red ADVANCE (CAT) Project COMRDI15-1-0013 from Ris3CAT, and 2014SGR364 research grant from the “Generalitat de Catalunya,” cofunded by the European Regional Development Fund, a way to Build Europeca_ES
dc.language.isoengca_ES
dc.publisherHindawica_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1155/2017/3615729ca_ES
dc.relation.ispartofStem Cells International, 2017, vol. 2017, ID. 3615729ca_ES
dc.rightscc-by (c) Moreno et al., 2017ca_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.otherCèl·lules mare mesenquimàtiquesca_ES
dc.titleHuman Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirusca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.1155/2017/3615729


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

cc-by (c) Moreno et al., 2017
Except where otherwise noted, this item's license is described as cc-by (c) Moreno et al., 2017